(Q44800183)

English

Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors

scientific article published in January 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

0 references

author name string

David E Adson

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Matt G Kushner

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Kathryn M Eiben

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

S Charles Schulz

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Depression and Anxiety

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

121-126

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Quetiapine fumarate (Seroquel): a new atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1002%2FDA.10137

21 January 2018

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1002%2FDA.10137

21 January 2018

Movement Disorders Associated With the Serotonin Selective Reuptake Inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FDA.10137

21 January 2018

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FDA.10137

7 January 2021

based on heuristic

inferred from DOI database lookup

The selectivity of inclusion and exclusion criteria in bulimia nervosa treatment studies.

1 reference

https://api.crossref.org/works/10.1002%2FDA.10137

7 January 2021

based on heuristic

inferred from DOI database lookup

Comorbidity in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.10137

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel augmentation strategy for treating resistant major depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.10137

7 January 2021

based on heuristic

inferred from DOI database lookup

Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder.

1 reference

https://api.crossref.org/works/10.1002%2FDA.10137

7 January 2021

based on heuristic

inferred from DOI database lookup

The need for clinically relevant research on treatment-resistant depression.

1 reference

https://api.crossref.org/works/10.1002%2FDA.10137

7 January 2021

based on heuristic

inferred from DOI database lookup

What role do atypical antipsychotic drugs have in treatment-resistant depression?

1 reference

https://api.crossref.org/works/10.1002%2FDA.10137

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DA.10137

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44800183&oldid=2043354592"